Articles from Alterome Therapeutics, Inc.

Alterome Therapeutics, Inc., a clinical-stage precision oncology biotechnology company focused on discovering and developing alteration-specific therapeutics to target validated oncogenic drivers, today announced that the first clinical data from the Phase 1 dose-escalation portion of its ongoing Phase 1/1b clinical trial evaluating ALTA3263, an orally available KRAS-selective, pan-mutant (ON/OFF) inhibitor, will be presented in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. A second presentation will feature preclinical data demonstrating the antitumor activity of ALTA3263 as monotherapy and in combination with cetuximab and other targeted agents in colorectal and pancreatic cancer models.

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation therapies targeting oncogenic driver mutations for the treatment of cancer, today announced the appointment of Johanna Mylet, CPA, as Chief Financial Officer (CFO). In this role, Ms. Mylet will lead Alterome’s financial strategy and operations, including capital formation strategy and allocation, financing activities, investor relations, and other growth-oriented initiatives as the company advances its clinical-stage pipeline.

Alterome Therapeutics, a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that members of its management team will participate in one-on-one investor meetings at the following upcoming conferences:

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced the appointment of Leonardo Faoro, MD, MBA, as Chief Medical Officer (CMO). Most recently, Dr. Faoro was CMO at Quanta Therapeutics, where he oversaw the clinical development of several novel KRAS inhibitors. Dr. Faoro will lead the ongoing clinical development of ALTA3263, a pan-KRAS ON/OFF inhibitor, and ALTA2618, a mutation-selective inhibitor for AKT1-driven cancers, both currently in Phase 1/1b development with initial data expected in 2026.

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced the appointment of Jung Choi as Chief Executive Officer (CEO) and Richard Heyman, Ph.D., as Chair of the Board of Directors.

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that the first patient has been dosed in the Phase 1/1b trial of ALTA3263 in adults with KRAS mutant solid tumors.

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced that senior management will participate in TD Cowen 45th Annual Health Care Conference and Leerink Partners Global Healthcare Conference 2025. Members of Alterome management will participate in one-on-one investor meetings at both conferences. Details of participation are as follows:

Alterome Therapeutics, Inc., a clinical stage biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the dosing of the first patient in AKTive-001, a Phase 1/1b trial of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced that data from preclinical studies of ALTA3263, the Company’s potential best-in-class KRAS selective inhibitor, will be presented in a plenary oral session at the EORTC-NCI-AACR (ENA) Symposium, taking place on October 23-25 in Barcelona, Spain.

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, announced today that Goldman Sachs (NYSE:GS) recognized Eric Murphy, Ph.D., CEO and co-founder of Alterome, as one of the Most Exceptional Entrepreneurs of 2024 at its Builders and Innovators Summit in Healdsburg, California.

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today reported promising preclinical data from their lead pipeline candidate, ALTA-2618, a mutation-selective inhibitor for AKT1 E17K driven cancers. The data are being presented in a poster presentation on April 8th at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego, CA on April 5-10, 2024.

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing. Proceeds from the fundraise will be used to support the advancement of multiple wholly-owned pipeline programs into the clinic, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor.

Alterome Therapeutics, Inc., a next-generation precision oncology company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the appointment of Andrew S. Chi, M.D., Ph.D., as its Chief Medical Officer.

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced the formation of the Company’s Scientific Advisory Board (SAB) with four esteemed oncology experts. The inaugural members of the SAB include Alterome co-founder Ryan Corcoran, M.D., Ph.D., Benjamin Cravatt, Ph.D., Paul Workman, Ph.D., and Keith Flaherty, M.D. The SAB will work closely with the Alterome management team to provide scientific and clinical guidance as the company advances its initial pipeline programs into the clinic.

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today announced that it has raised more than $35 million in a Series A2 financing, bringing total funds raised to nearly $100 million. Colt Ventures and OrbiMed co-led the round, with participation from all Series A investors including Nextech Invest, Vida Ventures, and Boxer Capital. The original round of $64 million closed in January 2022.

Alterome Therapeutics, Inc., a biopharmaceutical company developing alteration-specific targeted therapies for the treatment of cancer, announced the closing of a $64M Series A financing. The financing was led by OrbiMed, with participation from Nextech Invest, Vida Ventures, Boxer Capital, and others. Alterome Therapeutics was co-founded by Eric Murphy, Ph.D., and Ryan Corcoran, M.D., Ph.D.